Reha-Zentrum Gröbming
Gröbming, Styria, 8962, Austria
Location status: Recruiting
NCT Number: NCT07529054
Robotic-assisted gait training (RAGT) devices, such as the Lokomat®, are commonly used to support gait rehabilitation by enabling repetitive, task-specific walking movements. The functional proprioceptive stimulation (FPS) device Vibramoov® represents a novel technology designed to stimulate proprioceptors at the muscle-tendon junction through targeted vibratory stimuli, thereby activating sensorimotor centers in the brain and potentially facilitating movement execution.
The aim of this randomized controlled trial is to investigate whether Lokomat® training combined with Vibramoov® leads to greater improvements in qualitative and quantitative gait parameters in stroke patients compared with Lokomat® training alone. The study will be conducted at the Gröbming Rehabilitation Center and will include patients undergoing a four-week neurological inpatient rehabilitation program. Participants will be randomly assigned to an intervention group (Lokomat® + Vibramoov®) or a control group (Lokomat® only), with 20 patients per group.
Primary outcomes include the 6-Minute Walk Test (6MWT) and spatiotemporal gait parameters. Additional assessments include functional scores, patient-reported outcome measures, and blood biomarkers. Statistical analyses will be performed depending on data distribution. A follow-up assessment evaluating EQ-5D and PHQ-4 will be conducted six months after completion of the rehabilitation program.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Gröbming, Styria, 8962, Austria
Location status: Recruiting
Stroke is the most common cause of physical disability in Western industrialized countries, with approximately 70% of patients experiencing moderate to severe physical impairments [1]. In addition to the negative impact on mobility and balance, activities of daily living are often affected [2]. In particular, gait impairments-manifested, for example, by reduced walking speed or shortened step length-can significantly reduce the quality of life of patients after stroke [2,3]. Therefore, the restoration of a physiological gait pattern in terms of both qualitative and quantitative parameters represents a key objective of post-stroke rehabilitation.
In addition to conventional therapeutic approaches, robotic-assisted gait training (RAGT) devices such as the Lokomat® are frequently used [4]. With this device, patients are able to walk actively on a treadmill while being supported by an exoskeleton that simulates a symmetrical, bilateral gait pattern [3]. RAGT devices aim to improve walking by enabling a high number of repetitions of task-oriented movements, thereby facilitating the relearning of movement patterns [5].
Novel technologies such as the functional proprioceptive stimulation (FPS) device Vibramoov® may have the potential to enhance the effectiveness of RAGT. This therapeutic device aims to stimulate proprioceptors located at the muscle-tendon junction through targeted vibratory stimuli, thereby activating sensorimotor centers in the brain via afferent Ia fibers [6]. As a result, the execution of movements-for example during walking-may be facilitated. According to the manufacturer, Vibramoov® can be used during walking on level ground, during treadmill walking, or in combination with the Lokomat®. However, to date there is no research investigating the effects of Vibramoov® on gait parameters in stroke patients undergoing inpatient rehabilitation.
The aim of the present study is therefore to contribute to the investigation of FPS as a potential approach to maximize the effectiveness of RAGT. The primary research question is: Does Lokomat® training combined with the Vibramoov® device have a greater effect on qualitative and quantitative gait parameters in patients after stroke compared with Lokomat® training alone? To address this research question, a randomized controlled trial will be conducted at the Gröbming Rehabilitation Center. Patients after stroke who are undergoing a four-week neurological inpatient rehabilitation program will be randomly assigned to either an intervention group or a control group. Based on data regarding the effect of RAGT on the 6-Minute Walk Test (6MWT), and accounting for potential dropouts, a sample size of 20 patients per group was calculated [4].
Patients in both groups will receive the conventional rehabilitation program according to the medical service profile, in which RAGT represents part of the standard treatment for stroke patients with gait impairments. Patients in the control group will perform RAGT using the Lokomat®, while patients in the intervention group will perform RAGT using the Lokomat® in combination with Vibramoov®. The extent of RAGT will be identical in both groups.
The effects of the intervention will be quantified using several outcome parameters, including the 6-Minute Walk Test (6MWT) and spatiotemporal gait parameters. In addition, various functional scores and patient-reported outcome measures will be collected, and laboratory parameters and blood biomarkers will be analyzed. Depending on the distribution of the data, standard statistical methods such as the independent t-test or the Mann-Whitney U test will be applied to address the research question. A follow-up assessment six months after completion of the study (telephone interview) evaluating EQ-5D and PHQ-4 is planned.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The conventional Robotic Assisted Gait Training is combined with vibrational stimuli which is a novel approach.
Conventional Robotic Assisted Gait Training with the Lokomat
Time frame: At baseline and 4 weeks later after intervention
STGP, such as cadence or step lenght measured in a clinical gait analysis by a pressure measuring plate.
Time frame: At baseline and 4 weeks later after intervention
The 6MWT is a simple functional exercise test used to assess a person's walking capacity and endurance. It measures the distance a patient can walk in six minutes on a flat surface and reflects their submaximal level of functional capacity.
Time frame: At baseline and 4 weeks later after intervention
Biomarker measured in the serum, which is an indicator of the amount of neuroplasticity in the central nervous system.
Time frame: At baseline and 4 weeks later after intervention
Routine laboratory parameter, such as inflammatory markers measured in the serum.
Time frame: At baseline and 4 weeks later after intervention
Assessment for evaluation of balance and risk of falls.
Time frame: At baseline and 4 weeks later after intervention
FAC is a clinical scale used to assess a patient's walking ability and level of assistance required for ambulation.
Time frame: At baseline and 4 weeks later after intervention
The PHQ-4 is a brief screening questionnaire for anxiety and depression.
Time frame: At baseline and 4 weeks later after intervention
The EQ-5D is a standardized questionnaire used to measure health-related quality of life.
Contact information is provided by the study sponsor or research team.
Ludwig Boltzmann Institute for Arthritis and Rehabilitation
Network
The Potential of Robotic-Assisted Gait Training in a Rehabilitation Settin
Acronym: RAGT_RGB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05378035
Arrhythmias, Cardiac, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT03821129
Brain Diseases, Cardiovascular Abnormalities
Tucson, Arizona, United States
View Trial DetailsNCT06615973
Brain Disease, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07737431
Brain Diseases, Cardiovascular Diseases
Hung Hom, Kowloon, Hong Kong
View Trial Details